A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.
Nat Med
; 27(12): 2212-2223, 2021 12.
Article
in En
| MEDLINE
| ID: mdl-34887574
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Skin Neoplasms
/
Adjuvants, Immunologic
/
Cancer Vaccines
/
Indoleamine-Pyrrole 2,3,-Dioxygenase
/
B7-H1 Antigen
/
Nivolumab
/
Immune Checkpoint Inhibitors
/
Melanoma
Type of study:
Clinical_trials
Limits:
Humans
Language:
En
Journal:
Nat Med
Journal subject:
BIOLOGIA MOLECULAR
/
MEDICINA
Year:
2021
Document type:
Article
Affiliation country: